AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in Paris and will be considered for roll out across International markets, as ...

The National Medical Commission has launched an investigation into doctors whose foreign trips, funded by AbbVie Healthcare, ...

These 5 companies have not missed on earnings in 5 years. That's an impressive feat with the pandemic hitting in 2020.

The National Medical Commission (NMC) has started its probe against 30 doctors who allegedly took pharma freebies in the form ...

Jan. 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company ... launch of the first neuromodulator in aesthetic medicine: BOTOX® Cosmetic from Allergan Aesthetics.

Revance manufactures Daxxify, which competes with AbbVie's Botox, while Tennessee-based Crown makes various skincare and aesthetics products like SkinPen for microneedling and anti-aging cream ...